Logo image of QURE

UNIQURE NV (QURE) Stock Fundamental Analysis

NASDAQ:QURE - Nasdaq - NL0010696654 - Common Stock - Currency: USD

13.28  -0.17 (-1.26%)

After market: 13.2 -0.08 (-0.6%)

Fundamental Rating

2

QURE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. QURE has a bad profitability rating. Also its financial health evaluation is rather negative. QURE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

QURE had negative earnings in the past year.
QURE had a negative operating cash flow in the past year.
In the past 5 years QURE reported 4 times negative net income.
QURE had negative operating cash flow in 4 of the past 5 years.
QURE Yearly Net Income VS EBIT VS OCF VS FCFQURE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

QURE's Return On Assets of -34.02% is fine compared to the rest of the industry. QURE outperforms 62.07% of its industry peers.
Industry RankSector Rank
ROA -34.02%
ROE N/A
ROIC N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QURE Yearly ROA, ROE, ROICQURE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

QURE has a better Gross Margin (82.61%) than 86.75% of its industry peers.
QURE's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
QURE Yearly Profit, Operating, Gross MarginsQURE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for QURE has been increased compared to 1 year ago.
Compared to 5 years ago, QURE has more shares outstanding
QURE has a worse debt/assets ratio than last year.
QURE Yearly Shares OutstandingQURE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
QURE Yearly Total Debt VS Total AssetsQURE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -2.31, we must say that QURE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of QURE (-2.31) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.31
ROIC/WACCN/A
WACC6.62%
QURE Yearly LT Debt VS Equity VS FCFQURE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 9.98 indicates that QURE has no problem at all paying its short term obligations.
The Current ratio of QURE (9.98) is better than 78.58% of its industry peers.
QURE has a Quick Ratio of 9.98. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
QURE has a Quick ratio of 9.98. This is in the better half of the industry: QURE outperforms 78.58% of its industry peers.
Industry RankSector Rank
Current Ratio 9.98
Quick Ratio 9.98
QURE Yearly Current Assets VS Current LiabilitesQURE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.57% over the past year.
Looking at the last year, QURE shows a very negative growth in Revenue. The Revenue has decreased by -48.25% in the last year.
QURE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.01% yearly.
EPS 1Y (TTM)33.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.52%
Revenue 1Y (TTM)-48.25%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%-52.71%

3.2 Future

The Earnings Per Share is expected to decrease by -52.47% on average over the next years. This is quite bad
Based on estimates for the next years, QURE will show a very strong growth in Revenue. The Revenue will grow by 78.82% on average per year.
EPS Next Y26.42%
EPS Next 2Y17.29%
EPS Next 3Y15.25%
EPS Next 5Y-52.47%
Revenue Next Year-47.3%
Revenue Next 2Y41.31%
Revenue Next 3Y49.93%
Revenue Next 5Y78.82%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
QURE Yearly Revenue VS EstimatesQURE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
QURE Yearly EPS VS EstimatesQURE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

QURE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QURE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QURE Price Earnings VS Forward Price EarningsQURE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QURE Per share dataQURE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as QURE's earnings are expected to grow with 15.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.29%
EPS Next 3Y15.25%

More info and screens

0

5. Dividend

5.1 Amount

QURE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNIQURE NV

NASDAQ:QURE (8/8/2025, 6:32:47 PM)

After market: 13.2 -0.08 (-0.6%)

13.28

-0.17 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-29 2025-07-29/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners91.37%
Inst Owner Change0.21%
Ins Owners1.66%
Ins Owner Change3.02%
Market Cap728.67M
Analysts84
Price Target35.7 (168.83%)
Short Float %16.95%
Short Ratio7.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.2%
Min EPS beat(2)20.04%
Max EPS beat(2)24.35%
EPS beat(4)3
Avg EPS beat(4)-20.97%
Min EPS beat(4)-139.62%
Max EPS beat(4)24.35%
EPS beat(8)4
Avg EPS beat(8)-24.85%
EPS beat(12)6
Avg EPS beat(12)-25.57%
EPS beat(16)9
Avg EPS beat(16)-9.21%
Revenue beat(2)0
Avg Revenue beat(2)-42.73%
Min Revenue beat(2)-75.51%
Max Revenue beat(2)-9.94%
Revenue beat(4)0
Avg Revenue beat(4)-55.95%
Min Revenue beat(4)-75.51%
Max Revenue beat(4)-9.94%
Revenue beat(8)3
Avg Revenue beat(8)-26.26%
Revenue beat(12)4
Avg Revenue beat(12)-7.79%
Revenue beat(16)5
Avg Revenue beat(16)5.86%
PT rev (1m)0%
PT rev (3m)-1.16%
EPS NQ rev (1m)-2.02%
EPS NQ rev (3m)7.1%
EPS NY rev (1m)0%
EPS NY rev (3m)8.5%
Revenue NQ rev (1m)-8.13%
Revenue NQ rev (3m)-33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-52.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 50.82
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.94
EYN/A
EPS(NY)-3.09
Fwd EYN/A
FCF(TTM)-3.18
FCFYN/A
OCF(TTM)-3.16
OCFYN/A
SpS0.26
BVpS-0.07
TBVpS-1.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.61%
FCFM N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.2%
Cap/Sales 5.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.98
Quick Ratio 9.98
Altman-Z -2.31
F-Score4
WACC6.62%
ROIC/WACCN/A
Cap/Depr(3y)98.33%
Cap/Depr(5y)124.6%
Cap/Sales(3y)24.73%
Cap/Sales(5y)20.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.52%
EPS Next Y26.42%
EPS Next 2Y17.29%
EPS Next 3Y15.25%
EPS Next 5Y-52.47%
Revenue 1Y (TTM)-48.25%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%-52.71%
Revenue Next Year-47.3%
Revenue Next 2Y41.31%
Revenue Next 3Y49.93%
Revenue Next 5Y78.82%
EBIT growth 1Y30.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.03%
EBIT Next 3Y16.43%
EBIT Next 5Y50.02%
FCF growth 1Y30.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.43%
OCF growth 3YN/A
OCF growth 5YN/A